Option Care Health Announces Preliminary Financial Results for Fourth Quarter and Full Year 2024 and Preliminary Financial Expectations for Full Year 2025

Core Viewpoint - Option Care Health, Inc. announced preliminary unaudited financial results for Q4 and full year 2024, highlighting significant revenue growth and a new share repurchase program [1][4][5]. Financial Results Summary - For Q4 2024, the company expects net revenue between $1.34 billion and$1.35 billion, reflecting a growth of approximately 19.2% to 20.1% compared to Q4 2023 [8]. - Net income for Q4 2024 is projected to be between $56.8 million and$60.9 million, translating to diluted earnings per share of $0.33 to$0.36 [8]. - Adjusted net income for Q4 2024 is anticipated to be between $71.0 million and$76.8 million, with adjusted diluted earnings per share ranging from $0.42 to$0.45 [8]. - Adjusted EBITDA for Q4 2024 is expected to be between $118.7 million and$121.7 million, indicating a 6.4% to 9.1% increase over Q4 2023 [8]. Full Year 2024 Results - For the full year 2024, net revenue is expected to be approximately $4.99 billion to$5.00 billion, representing a growth of about 16.0% to 16.2% year-over-year [8]. - Net income for the full year is projected to be between $208.5 million and$212.6 million, with diluted earnings per share of $1.21 to$1.23 [8]. - Adjusted net income for the full year is anticipated to be between $268.3 million and$274.1 million, with adjusted diluted earnings per share ranging from $1.55 to$1.59 [8]. - Adjusted EBITDA for the full year is expected to be between $441.0 million and$444.0 million, reflecting a 3.7% to 4.4% increase compared to the previous year [8]. 2025 Guidance - For full year 2025, the company anticipates a negative gross profit impact of approximately $60 million to$70 million due to pricing adjustments related to Stelara [4]. - Further details regarding 2025 financial guidance will be provided during the fourth quarter earnings call in February [4]. Share Repurchase Program - In Q4 2024, the company completed $90 million of share repurchases under its previous program and has authorized a new$500 million stock repurchase program with no specified expiration date [5]. Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, and will release full Q4 and full year results on February 26, 2025 [6][7].